Clinical Trial

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-10-04; most recent amendment 2026-02-03.
Status change: Not Yet Recruiting → Recruiting 2024-10-22
Trial Details
NCT Number NCT06630234
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Gastrointestinal Stromal Tumor (GIST)
Enrollment 120 participants
Start Date 2024-12-10
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-05